NASDAQ: CLYMClimb Bio Inc Stock
$1.19+0.00 (+0%)
Updated May 9, 2025
CLYM Price
$1.19
Fair Value Price
$1.80
Market Cap
$80.30M
52 Week Low
$1.05
52 Week High
$9.58
P/E
-0.78x
P/B
0.38x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$73.90M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
-$16M
Beta
0.68
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
CLYM Overview
Eliem Therapeutics, Inc., a clinical-stage biotechnology company, develops therapies to address unmet needs in chronic pain, neuropsychiatry, epilepsy, and other for neuronal excitability disorders of the peripheral and central nervous systems. Its two lead drug candidates are ETX-810 and ETX-155. The company also develops preclinical pipeline programs, such as the Kv7 Program and Anxiolytic. Eliem Therapeutics was incorporated in 2018 and is headquartered in Redmond, WA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine CLYM's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
CLYM
Ranked#262 of 458
Ranked#262 of 458
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $1.72 | A | |
| $44.23 | A | |
| $8.00 | A |
Be the first to know about important CLYM news, forecast changes, insider trades & much more!
CLYM News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how CLYM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CLYM ($1.19) is undervalued by 33.89% relative to our estimate of its Fair Value price of $1.80 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CLYM ($1.19) is significantly undervalued by 33.89% relative to our estimate of its Fair Value price of $1.80 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CLYM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CLYM due diligence checks available for Premium users.
Valuation
CLYM fair value
Fair Value of CLYM stock based on Discounted Cash Flow (DCF)
Price
$1.19
Fair Value
$1.80
Undervalued by
33.89%
CLYM ($1.19) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CLYM ($1.19) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CLYM is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CLYM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.78x
Industry
-160.18x
Market
24.91x
CLYM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.38x
Industry
4.11x
CLYM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CLYM's financial health
Profit margin
Revenue
$0.0
Net Income
-$8.4M
Profit Margin
0%
CLYM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$217.2M
Liabilities
$5.3M
Debt to equity
0.03
CLYM's short-term assets ($154.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CLYM's short-term assets ($154.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CLYM's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
CLYM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$5.5M
Investing
-$53.4M
Financing
$41.0k
CLYM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CLYM vs Biotech Stocks
Climb Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.